896 abstracts found.
Results filter
- Year: 2014 Remove Filter
Computational dissection of intratumour genetic heterogeneity and applications to the study of cancer treatment, evolution and metastasis
What can we learn from circulating tumour cells in lung cancer – biomarkers, mouse models, drug resistance and heterogeneity
The targets for tumour immunotherapy mediated by the inflammatory properties of vesicular stomatitis virus (VSV)-based antigen presentation depend upon the tumour’s anatomical site
Introduction: Optimising care for those living with and beyond cancer – where does primary care fit in?
Primary care views on optimising care for those living with and beyond cancer: findings from a systematic review and GP survey
BACR Tom Connors lecture – Targeting and imaging cancer phenotypes: Focal Adhesion Kinase as a critical regulator of tumour cells and the host immune response
Year: 2014
Session type: Plenary lectures
1Cancer Research UK Edinburgh Centre, University of Edinburgh, Edinburgh, UK
Cancer genomics: state of the science and clinical translation
Year: 2014
Session type: Plenary lectures
1The Genome Institute at Washington University School of Medicine, St Louis, USA
Targeting phosphoinositide 3-kinase for cancer therapy
Year: 2014
Session type: Plenary lectures
1Weill Cornell Medical School, Cornell University, New York, USA
Targeting phosphoinositide 3-kinase for cancer therapy
Year: 2014
Session type: Plenary lectures
1Weill Cornell Medical School, Cornell University, New York, USA
Circulating cell-free DNA as a strong multimarker diagnostic, theranostic and prognostic tool for metastatic colorectal cancer patients management care
Whither drug discovery: the genetic basis for cancer therapeutics
Year: 2014
Session type: Plenary lectures
1Novartis Institutes for BioMedical Research, Cambridge, USA
Mouse models of malignant glioblastoma multiforme: cancer stem cells and beyond
Year: 2014
Session type: Plenary lectures
1University of Texas Southwestern Medical Center, Dallas, USA
Pan-RAF inhibitor active in melanomas that are resistant to BRAF or BRAF /MEK inhibitor combinations.
Year: 2014
Session type: Parallel sessions
1Molecular Oncology Group - Cancer Research UK Manchester Institute, Manchester, UK,2Gene and Oncogene Targeting Team - The Institute of Cancer Research, London, UK,3Signal Transduction Team - Cancer Research UK Manchester Institute, Manchester, UK,4Targeted Therapy Team - The Institute of Cancer Research, London, UK,5University of Manchester - Christie NHS Foundation Trust, Manchester, UK
Mouse models of malignant glioblastoma multiforme
Year: 2014
Session type: Plenary lectures
1University of Texas Southwestern Medical Center, Dallas, USA